KR20220062688A - 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 - Google Patents

안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 Download PDF

Info

Publication number
KR20220062688A
KR20220062688A KR1020227015200A KR20227015200A KR20220062688A KR 20220062688 A KR20220062688 A KR 20220062688A KR 1020227015200 A KR1020227015200 A KR 1020227015200A KR 20227015200 A KR20227015200 A KR 20227015200A KR 20220062688 A KR20220062688 A KR 20220062688A
Authority
KR
South Korea
Prior art keywords
treatment
certain embodiments
ocular
topical
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227015200A
Other languages
English (en)
Korean (ko)
Inventor
아힘 한스-피터 크라우스
Original Assignee
악세로비젼, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악세로비젼, 인크. filed Critical 악세로비젼, 인크.
Publication of KR20220062688A publication Critical patent/KR20220062688A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227015200A 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물 Ceased KR20220062688A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
US62/189,813 2015-07-08
KR1020187003454A KR102440162B1 (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187003454A Division KR102440162B1 (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Publications (1)

Publication Number Publication Date
KR20220062688A true KR20220062688A (ko) 2022-05-17

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227015200A Ceased KR20220062688A (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
KR1020187003454A Active KR102440162B1 (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187003454A Active KR102440162B1 (ko) 2015-07-08 2016-07-07 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물

Country Status (21)

Country Link
US (3) US10413535B2 (https=)
EP (1) EP3319639B1 (https=)
JP (2) JP6752276B2 (https=)
KR (2) KR20220062688A (https=)
CN (1) CN107921136A (https=)
AU (1) AU2016290197B2 (https=)
BR (1) BR112018000112A2 (https=)
CA (1) CA2989522C (https=)
CL (1) CL2018000057A1 (https=)
ES (1) ES2835274T3 (https=)
HK (1) HK1247120A1 (https=)
IL (2) IL256770B (https=)
MA (2) MA42016A1 (https=)
MX (1) MX385229B (https=)
MY (1) MY187552A (https=)
PL (1) PL3319639T3 (https=)
RU (1) RU2018103940A (https=)
TN (1) TN2017000538A1 (https=)
UA (1) UA123728C2 (https=)
WO (1) WO2017006272A1 (https=)
ZA (1) ZA201708601B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
EP3624773A4 (en) * 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4541422A3 (en) 2018-10-30 2025-06-25 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
MX2022001062A (es) * 2019-07-26 2022-02-14 Allegro Pharmaceuticals Llc Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR20230110514A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 안구 장애의 치료를 위한 화합물 및 방법
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
UA123728C2 (uk) 2021-05-26
EP3319639B1 (en) 2020-11-18
US10413535B2 (en) 2019-09-17
RU2018103940A3 (https=) 2019-09-03
CA2989522C (en) 2022-10-18
IL256770A (en) 2018-03-29
KR20180041122A (ko) 2018-04-23
ES2835274T3 (es) 2021-06-22
IL280827A (en) 2021-04-29
AU2016290197A1 (en) 2018-01-04
MX2017017163A (es) 2018-08-09
WO2017006272A1 (en) 2017-01-12
CA2989522A1 (en) 2017-01-12
US20200000786A1 (en) 2020-01-02
JP2018521126A (ja) 2018-08-02
JP2020121985A (ja) 2020-08-13
PL3319639T3 (pl) 2021-03-08
AU2016290197B2 (en) 2021-07-22
CN107921136A (zh) 2018-04-17
ZA201708601B (en) 2019-05-29
TN2017000538A1 (en) 2019-04-12
US20200405703A1 (en) 2020-12-31
JP6752276B2 (ja) 2020-09-09
EP3319639A1 (en) 2018-05-16
KR102440162B1 (ko) 2022-09-02
MY187552A (en) 2021-09-29
RU2018103940A (ru) 2019-08-08
MX385229B (es) 2025-03-14
BR112018000112A2 (pt) 2018-09-04
IL256770B (en) 2021-02-28
MA42016A1 (fr) 2018-03-30
US20180200240A1 (en) 2018-07-19
CL2018000057A1 (es) 2018-06-22
MA44935A1 (fr) 2019-08-30
US10751334B2 (en) 2020-08-25
HK1247120A1 (zh) 2018-09-21

Similar Documents

Publication Publication Date Title
KR102440162B1 (ko) 안구 염증 병태의 치료에 사용하기 위한 인테그린 알파4 길항제를 포함하는 제약 조성물
US12496326B2 (en) Ophthalmic composition for treatment of dry eye disease
JP7116490B2 (ja) 眼の炎症性障害および疾患の組合せ処置
US20170290888A1 (en) Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
JP2025026942A (ja) 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸
EP4167965A1 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
OA19750A (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions.

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220504

Application number text: 1020187003454

Filing date: 20180205

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220603

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220614

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20221221

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230310

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20221221

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20220614

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I